We are live on ! Find out more
CSCI

COSCIENS Biopharma Inc. Common Stock
CSCI

Delisted

CSCI was delisted on the 3rd of September, 2025.

Back to rankings

10 hedge funds and large institutions have $1.24M invested in COSCIENS Biopharma Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

41% less funds holding

Funds holding: 17 → 10 (-7)

78% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 9

86% less capital invested

Capital invested by funds: $8.97M → $1.24M (-$7.73M)

Holders
10
Holders Change
-7
Holders Change %
-41.18%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
3
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.1M
2
Deutsche Bank
Deutsche Bank
Germany
+$131K
3
Creative Planning
Creative Planning
Kansas
+$42.1K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$4.21K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.43M
2
TCM
Tenor Capital Management
New York
-$3.07M
3
DM
Deerfield Management
New York
-$482K
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$154K
5
Millennium Management
Millennium Management
New York
-$79K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$893K +$1.1M +262 +468%
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$116K -$3.43M -813 -95%
Deutsche Bank
3
Deutsche Bank
Germany
$88K +$131K +31 New
NCCM
4
Nine Chapters Capital Management
New Jersey
$84K -$29.5K -7 -19%
Creative Planning
5
Creative Planning
Kansas
$28K +$42.1K +10 New
Cambridge Investment Research Advisors
6
Cambridge Investment Research Advisors
Iowa
$8K +$4.21K +1 +50%
Ameriprise
7
Ameriprise
Minnesota
$7K -$8.43K -2 -50%
AAM
8
Azzad Asset Management
Virginia
$6.08K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$3K – – –
Morgan Stanley
10
Morgan Stanley
New York
$1K -$4.21K -1 Closed
Bank of Montreal
11
Bank of Montreal
Ontario, Canada
$1K – – –
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$1K – – –
Wells Fargo
13
Wells Fargo
California
$1K – – –
AIG
14
American International Group
New York
$365 – – –
TCM
15
Tenor Capital Management
New York
– -$3.07M -573 Closed
DM
16
Deerfield Management
New York
– -$482K -90 Closed
Hudson Bay Capital Management
17
Hudson Bay Capital Management
Connecticut
– -$154K -29 Closed
Millennium Management
18
Millennium Management
New York
– -$79K -15 Closed
TSS
19
Two Sigma Securities
New York
– -$18K -3 Closed
AL
20
Airain Ltd
Guernsey
– -$11K -2 Closed
Bank of America
21
Bank of America
North Carolina
– -$8.43K -2 Closed
CT
22
Cambridge Trust
Massachusetts
– -$5K -1 Closed

CSCI Hedge Fund Activity: Q2 2015 in Review

10 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q2 2015, worth a combined $1.24M — down 86% from $8.97M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of CSCI and 2 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $1.1M. The largest seller was Susquehanna International Group, cutting an estimated $3.43M.

  • 10 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q2 2015, down from 17 in Q1 2015.
  • Funds reported $1.24M of COSCIENS Biopharma Inc. Common Stock stock for Q2 2015, down 86% quarter-over-quarter.
  • 2 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q2 2015 and 9 closed out, a net change of -7 holders.
  • The largest COSCIENS Biopharma Inc. Common Stock buyer in Q2 2015 was Renaissance Technologies, an estimated $1.1M added.
  • The largest COSCIENS Biopharma Inc. Common Stock seller in Q2 2015 was Susquehanna International Group, an estimated $3.43M sold.

Based on aggregated 13F filings for Q2 2015.